POST SUMMARY: Consumers don’t trust big pharma, but hey are going online in bigger numbers to get health information. If we want to be part of the conversation we need to EARN their trust one patient at a time. It’s not going to be easy, but we need to fight for patients at every meeting and within every online digital interaction.
POST SUMMARY: A guest post, last week, on the digital pharma conference led to a lot of comments with very strong opinions on both sides. The author sent me the post on condition that he would remain anonymous because his company does not allow employees to write articles without first going through a maze of approvals. However, he does raise some very good points.
Those who access health content are also doing so using more than just PCs. In April 2013, 35 percent of visitors used mobile devices to consume health information. A year later, almost half of health information-seekers used mobile devices to consume health content. This uptick in mobile usage suggests two things: an increased reliance in managing one’s health issues on-the-go, and an increase in tablet usage at home instead of the PC. For those using mobile devices out-of-home to manage health issues, uses included understanding symptoms, treating a condition, or achieving one’s health goals. Comscore’s research indicates more specifically that on-the-go mobile users seek health information at doctor’s offices and while waiting for prescription refills at the pharmacy.
POST SUMMARY: WebMD Health Corp. said it is suing Everyday Health Inc for trademark infringement, false advertising and unfair competition. This is very much the battle for ad dollars as well as stock price and the outcome should be interesting.
POST SUMMARY: Big pharma companies continue to be defined by a myriad of external sources from Congress, questioning high drug prices, to seemingly unorthodox behavior like putting profits over patient safety as in the Boehringer Ingelheim Pradaxa case. However, biotech companies like Biogen continue to develop and market new drugs by tossing out the big pharma business models and focusing on patients.
The IMS Institute of Health Informatics released a report today called “riding the technology wave in life sciences” and there are some troubling findings. Among one of their key findings “despite abundant and growing amounts of data being generated and accessed by life sciences companies, analytic systems designed to interpret and create actionable insights have not kept pace.”